Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Cell. 2018 Dec 13;175(7):1720-1722. doi: 10.1016/j.cell.2018.11.048.

NKG2A, a New Kid on the Immune Checkpoint Block.

Author information

1
Medical Oncology and Molecular Oncology & Immunology Divisions, The Netherlands Cancer Institute, Amsterdam, NL. Electronic address: j.haanen@nki.nl.
2
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, UK.

Abstract

One of the major breakthroughs of cancer immunotherapy has come from blocking immune checkpoint molecules on tumor-reactive T cells. Now, two studies examine targeting of a novel immune checkpoint, NKG2A, that can be expressed on both NK cells and on CD8+ T cells, either combined with a tumor-targeting antibody or with a tumor-specific vaccine.

PMID:
30550781
DOI:
10.1016/j.cell.2018.11.048

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center